• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthCoronavirus

We don’t know enough about COVID antibodies to count on them

By
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Down Arrow Button Icon
October 28, 2020, 6:30 PM ET

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism, subscribe today.

One of the biggest outstanding questions about the coronavirus, and one which could well determine the course of the pandemic, is the role that antibodies play in immunity.

By now you’ve probably heard plenty about antibodies in the context of immunity and developing a COVID vaccine. These Y-shaped proteins form because of an immune response to a pathogen or other hostile biological material. They may be personalized to sites on an individual virus called antigens, to which they attach and help prevent infection.

As with many viruses, antibodies form during the course of a COVID case and should offer protection against against a second coronavirus infection. But it’s still unclear just how potent these antibodies are and whether or not they may provide stronger immunity for some people more than others. And that raises the question of whether or not you can contract COVID-19 twice.

One central mystery that may take years to answer is how long COVID antibodies last. First off, antibodies don’t always behave the same everyone. Some may form powerful antibodies with staying power; others whose body’s so-called adaptive immune system produces weaker ones may face a much more brutal fight with COVID and be at a higher risk for reinfection. Human biology can react in unpredictable ways to new adversaries.

Then there’s the type of pathogen that the novel coronavirus is itself. Coronaviruses encompass a broad class of bugs which can include everything from some types of the common cold to SARS and MERS. There is to date no cure or vaccine for the common cold since there is such a variety of strains. There also aren’t any commercially available ones for SARS or MERS—or any coronaviruses for that matter.

Part of the reason for that is both the SARS and MERS outbreaks cause milder disease than COVID-19, and the former were contained relatively quickly. Patients who contracted SARS during that outbreak were found that have protective antibodies for an average of two years.

That doesn’t seem to be the case with the novel coronavirus—at least for certain COVID patients. In those who suffer from a mild case, antibody levels may be cut in half in just over two months, according to one study in the New England Journal of Medicine.

Another new analysis by Imperial College London scientists released this week examined antibody levels among the British population. The report found that antibody prevalence dropped sharply and quickly in the study population: from 6% in late June to 4.4% in late September.

“This very large study has shown that the proportion of people with detectable antibodies is falling over time,” said Helen Ward, one of the lead study authors.

But there’s another twist: Those falling antibody levels don’t necessarily mean you’ll be reinfected with COVID. “We don’t yet know whether this will leave these people at risk of reinfection with the virus that causes COVID-19, but it is essential that everyone continues to follow guidance to reduce the risk to themselves and others,” she said.

Other studies have shown there is a non-zero number of people who have been reinfected after recovering from COVID. A Lancet report published two weeks ago examined the case of a 25-year-old man from Washoe County in Nevada who contracted COVID-19 once in April and again at the end of May.

“The degree of protective immunity conferred by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently unknown. As such, the possibility of reinfection with SARS-CoV-2 is not well understood,” wrote the authors from the University of Nevada and Nevada State Public Health Library.

To date, as the Centers for Disease Control (CDC) puts it, “confirmed and suspected cases of reinfection of the virus that causes COVID-19 have been reported, but remain rare​.”​

Experts stress that the mere presence of coronavirus antibodies is no reason to assume you’ll have long-lasting immunity or protect others from infection. The latter point throws a big wrench into proponents of a “herd immunity” approach wherein you simply let enough people get infected and become immune.

At the end of the day, it is still be important to wash your hands, wear a mask, socially distance, and be generally responsible—antibodies or otherwise.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.


Most Popular

placeholder alt text
Success
Billionaire philanthropy's growing divide: Mark Zuckerberg stops funding immigration reform as MacKenzie Scott doubles down on DEI
By Ashley LutzDecember 22, 2025
1 day ago
placeholder alt text
Success
Former U.S. Secret Service agent says bringing your authentic self to work stifles teamwork: 'You don’t get high performers, you get sloppiness'
By Sydney LakeDecember 22, 2025
1 day ago
placeholder alt text
Travel & Leisure
After pouring $450 million into Florida real estate, Larry Ellison plans to lure the ultrarich to an exclusive town just minutes from Mar-a-Lago
By Marco Quiroz-GutierrezDecember 22, 2025
1 day ago
placeholder alt text
Economy
Mitt Romney says the U.S. is on a cliff—and taxing the rich is now necessary 'given the magnitude of our national debt'
By Dave SmithDecember 22, 2025
1 day ago
placeholder alt text
Success
'When we got out of college, we had a job waiting for us': 80-year-old boomer says her generation left behind a different economy for her grandkids
By Mike Schneider and The Associated PressDecember 23, 2025
11 hours ago
placeholder alt text
Success
Multimillionaire musician Will.i.am says work-life balance is for people ‘working on someone else’s dream’ and not for visionaries—he grinds from 5-to-9 after his 9-to-5
By Orianna Rosa RoyleDecember 21, 2025
2 days ago

Latest in Health

Best protein lead image
HealthDietary Supplements
The 9 Best Protein Powders of 2025: How to Choose, According to an RD
By Christina SnyderDecember 23, 2025
4 hours ago
Transparent Labs Creatine HMB as best creatine
HealthDietary Supplements
The Best Creatine Supplements of 2025: Tested and Approved
By Christina SnyderDecember 23, 2025
4 hours ago
HealthDietary Supplements
The Best Hair Loss Treatments of 2025: Tested and Approved by Experts
By Christina SnyderDecember 23, 2025
5 hours ago
Hims Hair loss treatment
HealthDietary Supplements
Hims Hair Loss Review 2025: Pros, Cons, and More From Hands-On Testing
By Christina SnyderDecember 22, 2025
1 day ago
David Ko stands in front of a blue and purple "Fortune" background.
Healthchief executive officer (CEO)
The CEO behind the world’s top sleep and meditation app says most leaders are operating at ‘about 20%’ without a ‘fully recharged’ battery
By Sasha RogelbergDecember 19, 2025
5 days ago
Johnson
PoliticsCongress
Republican leaders powerless to stop a January vote on healthcare after moderates defect on ACA subsidies
By Joey Cappelletti and The Associated PressDecember 18, 2025
5 days ago